· · · · · · · · · · · · · · · · · · ·	Application No.	Applicant(s)
		ALIZON ET AL
Notice of Allowability	07/158,652 Examiner	ALIZON ET AL. Art Unit
•		
	Jeffrey Fredman	1637
The MAILING DATE of this communication app All claims being allowable, PROSECUTION ON THE MERITS IS herewith (or previously mailed), a Notice of Allowance (PTOL-85 NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT R of the Office or upon petition by the applicant. See 37 CFR 1.31:	(OR REMAINS) CLOSED in or other appropriate commining or other appropriation is s	n this application. If not included unication will be mailed in due course. THIS
1. This communication is responsive to <u>June 5, 2006</u> .		
2. The allowed claim(s) is/are <u>142-151</u> .		
3. Acknowledgment is made of a claim for foreign priority u  a) All b) Some* c) None of the:		or (f).
<ol> <li>Certified copies of the priority documents have</li> <li>Certified copies of the priority documents have</li> </ol>		on No
Copies of the certified copies of the priority documents have      Copies of the certified copies of the priority documents.		
International Bureau (PCT Rule 17.2(a)).		d in this flational stage application from the
* Certified copies not received:		
Applicant has THREE MONTHS FROM THE "MAILING DATE" noted below. Failure to timely comply will result in ABANDONN THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		e a reply complying with the requirements
4.  A SUBSTITUTE OATH OR DECLARATION must be subm INFORMAL PATENT APPLICATION (PTO-152) which giv		
5. CORRECTED DRAWINGS ( as "replacement sheets") mu		
(a) including changes required by the Notice of Draftsper		v ( PTO-948) attached
1) hereto or 2) to Paper No./Mail Date	-	
(b) ☐ including changes required by the attached Examiner Paper No./Mail Date		
Identifying indicia such as the application number (see 37 CFR 1 each sheet. Replacement sheet(s) should be labeled as such in	1.84(c)) should be written on t the header according to 37 CF	he drawings in the front (not the back) of FR 1.121(d).
6. DEPOSIT OF and/or INFORMATION about the deposit attached Examiner's comment regarding REQUIREMENT		
•		
Attachment(c)		
Attachment(s) 1. ☐ Notice of References Cited (PTO-892)	5. Notice of In	formal Patent Application
2.  Notice of Draftperson's Patent Drawing Review (PTO-948)		ummary (PTO-413),
3. ☑ Information Disclosure Statements (PTO/SB/08),	Paper No. 7. ⊠ Examiner's	/Mail Date Amendment/Comment
Paper No./Mail Date 7/1/04  4. Examiner's Comment Regarding Requirement for Deposit of Biological Material	8. 🛛 Examiner's	Statement of Reasons for Allowance
	9.	- 1 -
		JEFFREY FREDMAN PRIMARY EXAMINER
		1.1.1.

Application/Control Number: 07/158,652 Page 2

Art Unit: 1637

## Inventorship

1. In view of the papers filed June 5, 2006, it has been found that this nonprovisional application, as filed, through error and without deceptive intent, improperly set forth the inventorship, and accordingly, this application has been corrected in compliance with 37 CFR 1.48(c). The inventorship of this application has been changed by the addition of:

Robert C. Gallo, Milkulas Popovic, Mangalasseril G. Sarngadharan, Solange Chamaret, Claudine Axler-Bin, Francoise Rey, Marie-Therese Nugeyre, Jacqueline Gruest, Charles Dauget, Willy Rozenbaum, Christine Rouzioux, Francoise Brun-Vezinet, Luc Montagnier, Jean-Claude Chermann Francoise Barre-Sinoussi, Pierre Tiollais.

The application will be forwarded to the Office of Initial Patent Examination (OIPE) for issuance of a corrected filing receipt, and correction of Office records to reflect the inventorship as corrected.

## **REASONS FOR ALLOWANCE**

2. The following is an examiner's statement of reasons for allowance: The current claims are drawn to specific HIV sequences and methods of using those sequences which were not taught or suggested by any prior art. The current applicants represent many of the original discoverers of HIV and the current application claims priority to those early dates. The BPAI awarded priority to the Chang application, but the currently claimed sequences all recite a portion of the HIV-1 LTR which is not taught or suggested by Chang, so Chang is not prior art. Further, in view of the terminal

Page 3

Application/Control Number: 07/158,652

Art Unit: 1637

disclaimers, there is no double patenting issues over related issued applications. The claims are enabled, novel and unobvious over the prior art.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jeffrey Fredman whose telephone number is (571)272-0742. The examiner can normally be reached on 6:30-3:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Benzion can be reached on (571)272-0782. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Jeffrey Fredman

JEFFREY FREDMAN PRIMARY EXAMINER

1015104